Cellectis (CLLS) is trading down at $1.41 (-1.40%), as of the latest quote. It operates in the Health Care sector.
Cellectis revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $44.8M | $25.2M | $12.7M | $15.2M | $51.1M | $30.3M | $19.2M | $755.0K | $41.5M | $72.9M |
| Growth (year over year) | −19.8% | −43.8% | −49.5% | +19.3% | +236.1% | −40.6% | −36.8% | −96.1% | +5397.4% | +75.8% |
| Gross profit | — | $22.6M | $9.99M | $3.80M | $49.1M | $28.5M | $17.4M | $18.0K | $41.5M | $72.9M |
| Gross margin | — | 89.6% | 78.5% | 25.0% | 96.2% | 93.9% | 90.8% | 2.4% | 100.0% | 100.0% |
| Operating income | −$67.3M | −$92.7M | −$105.1M | −$123.6M | −$42.3M | −$103.5M | −$89.7M | −$97.3M | −$59.6M | −$33.1M |
| Operating margin | −150.2% | −367.8% | −825.5% | −813.4% | −82.9% | −341.0% | −467.7% | −12887.7% | −143.5% | −45.3% |
| Net income | −$67.3M | −$99.4M | −$78.7M | −$102.1M | −$81.1M | −$114.2M | −$106.1M | −$101.1M | −$36.8M | −$67.6M |
| Net margin | −150.1% | −394.5% | −618.1% | −672.1% | −158.8% | −376.3% | −553.6% | −13385.3% | −88.6% | −92.7% |
| EPS (diluted) | −$1.91 | −$2.78 | −$1.93 | −$2.41 | −$1.91 | −$2.55 | −$2.33 | −$1.77 | −$0.41 | −$0.67 |
| Balance sheet | ||||||||||
| Cash and equivalents | $254.6M | $256.4M | $451.5M | $340.5M | $241.1M | $185.6M | $93.2M | $136.7M | $143.3M | $61.5M |
| Total assets | $331.4M | $332.9M | $535.0M | $467.5M | $469.5M | $382.1M | $261.2M | $334.3M | $383.5M | $324.7M |
| Total liabilities | $58.4M | $48.9M | $84.7M | $112.0M | $160.6M | $145.6M | $135.3M | $249.6M | $252.5M | $248.8M |
| Shareholders' equity | $272.8M | $264.9M | $409.3M | $315.1M | $283.8M | $221.3M | $118.0M | $84.7M | $131.0M | $75.9M |
| Cash flow | ||||||||||
| Operating cash flow | −$32.7M | −$52.3M | −$68.1M | −$69.1M | −$80.3M | −$104.6M | −$87.4M | −$24.7M | $23.0M | −$39.4M |
| Capital expenditure | $13.7M | $2.38M | $4.71M | $12.9M | $44.1M | $18.5M | $2.43M | $1.07M | $2.58M | $2.36M |
| Free cash flow | −$46.4M | −$54.7M | −$72.9M | −$82.1M | −$124.3M | −$123.1M | −$89.9M | −$25.8M | $20.4M | −$41.8M |
| Q2 FY23Jun 2023 | Q4 FY23Dec 2023 | Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $178.0K | — | $4.53M | $8.06M | — | $10.7M | $16.7M | — |
| Growth (year over year) | −86.4% | — | +3157.6% | +4428.7% | — | +135.3% | +107.5% | — |
| Gross profit | $123.0K | — | — | — | — | — | — | — |
| Gross margin | 69.1% | — | — | — | — | — | — | — |
| Operating income | −$23.6M | — | −$20.9M | −$17.2M | — | −$14.2M | −$9.59M | — |
| Operating margin | −13270.2% | — | −461.4% | −213.5% | — | −133.1% | −57.3% | — |
| Net income | −$11.7M | — | $5.64M | −$25.3M | — | −$18.1M | −$23.7M | — |
| Net margin | −6577.0% | — | 124.6% | −313.5% | — | −170.1% | −141.9% | — |
| EPS (diluted) | −$0.20 | — | $0.04 | −$0.28 | — | −$0.18 | −$0.24 | — |
| Balance sheet | ||||||||
| Cash and equivalents | $84.4M | $136.7M | — | $149.0M | $143.3M | — | $59.8M | $61.5M |
| Total assets | $227.7M | $334.3M | — | $407.1M | $383.5M | — | $354.0M | $324.7M |
| Total liabilities | $131.1M | $249.6M | — | $258.5M | $252.5M | — | $256.9M | $248.8M |
| Shareholders' equity | $96.6M | $84.7M | — | $148.6M | $131.0M | — | $97.1M | $75.9M |
From Cellectis's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Cellectis
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
- Headquarters
- Paris, Lle-De-France, France From SEC filings, Oct 2026
Recent News
No recent news mentioning Cellectis in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International